Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy

Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy

Purpose To evaluate Hyperthermic-Intra-Vesical Chemotherapy (HIVEC) efficacy regarding 1-year disease-free survival (RFS) rate and bladder preservation rate in patients with High-risk Non-Muscle Invasive Bladder Cancer (NMIBC) who fail BCG therapy or are contraindicated to BCG. Methods Between June...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Laure Doisy, Arnaud Cimier, Aurélien Adypagavane, Jochen Walz, Thibault Marquette, Thomas Maubon, Stanislas Rybikowski, Sami Fakhfakh, Kevin Loverde, Nicolas Mottet, Jacques Irani, Eric Lechevallier, Dominique Rossi, Gwenaelle Gravis, Géraldine Pignot
Formato: article
Lenguaje:EN
Publicado: Taylor & Francis Group 2021
Materias:
bladder cancer
bcg-refractory
cystectomy
chemohyperthermia
recurrence
progression
Medical technology
R855-855.5
Acceso en línea:https://doaj.org/article/2244ac07f40049d88cd6f64b4d121df2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/2244ac07f40049d88cd6f64b4d121df2

Ejemplares similares